Pharmacokinetics of once-daily trospium chloride 60 mg extended release and twice-daily trospium chloride 20 mg in healthy adults

Journal of Clinical Pharmacology

Volumn 50, Issue 2, 2010, Pages 143-150

  Silver, Nova ^a   Sandage, Bobby ^a   Sabounjian, Luann ^a   Schwiderski, Ute ^a   Shipley, James ^a   Harnett, Mark ^a  

^a Endo Pharmaceuticals Inc   (United States)

Author keywords

Extended release; Immediate release; Pharmacokinetics; Trospium chloride

Indexed keywords

TROSPIUM CHLORIDE;

ABDOMINAL AORTA BRUIT; ABDOMINAL PAIN; ADULT; AORTA DISEASE; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG RELEASE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEMATURIA; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; OUTCOME ASSESSMENT; PAIN; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STEADY STATE; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ADOLESCENT; ADULT; BIOLOGICAL AVAILABILITY; CAPSULES; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NORTROPANES; PARASYMPATHOLYTICS; TABLETS; YOUNG ADULT;

EID: 75749145862     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009345498     Document Type: Article

References (18)

1. Abrams P., Drake M. Overactive bladder. In: Wein AJ, Kavoussi LR, Novick AC, et al, eds. Campbell-Walsh Urology. 9 th ed. Philadelphia, PA: Saunders ; 2007: 2079-2090.
2. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003 ; 20: 327-336.
3. Hu TW, Wagner TH, Bentkover JD, Leblanc K., Zhou SZ, Hunt T. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology. 2004 ; 63: 461-465.
4. Chapple C., Khullar V., Gabriel Z., Dooley JA The effects of anti-muscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol. 2005 ; 48: 5-26.
5. Campbell UB, Stang P., Barron R. Survey assessment of continuation of and satisfaction with pharmacological treatment for urinary incontinence. Value Health. 2007 ; 11: 726-732.
6. Muller N. What Americans understand and how they are affected by bladder control problems: highlights of recent nationwide consumer research. Urol Nurs. 2005 ; 25: 109-115.
7. Pak RW, Petrou SP, Staskin DR Trospium chloride: a quaternary amine with unique pharmacologic properties. Curr Urol Rep. 2003 ; 4: 436-440.
8. Alloussi S., Baldauf J., Derouet H., Zwergel U., Meessen S. Effect of trospium chloride, oxybutynin and propiverine on the interaction of acetylcholine with isolated preparations of the human urinary bladder. Investigative Urology 4. Heidelberg: Springer-Verlag ; 1991: 157-161.
9. Foti A., Penazzo S., Volpe L. Use of a new spasmolytic agent (Spasmex) in obstetrics. Minerva Ginecol. 1971 ; 23: 480-488.
10. Osca Garcia JM, Martinez Agullo E., Conejero Sugranes J., Jimenez Cruz JF A comparison of trospium chloride and oxybutynin in the treatment of hyperactive bladder: a randomized double-blind study. Urod A. 1997 ; 10: 40-44.
11. Zinner N., Gittelman M., Harris R., Susset J., Kanelos A., Auerbach S. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol. 2004 ; 171 (6 pt 1). 2311-2315.
12. Rudy D., Cline K., Harris R., Goldberg K., Dmochowski R. Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology. 2006 ; 67: 275-280.
13. Staskin D., Sand P., Zinner N., Dmochowski R. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. J Urol. 2007 ; 178 (3 pt 1). 978-983.
14. Dmochowski RR, Sand PK, Zinner NR, Staskin DR Trospium 60 mg once daily (once daily) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology. 2008 ; 71: 449-454.
15. Maganti L., Panebianco DL, Maes AL Evaluation of methods for estimating time to steady state with examples from phase 1 studies. AAPS J. 2008 ; 10: 141-147.
16. MacDiarmid S., Sandage BW Jr, Malhotra BK The effects of reformulation: improved therapeutic index. Curr Urol Rep. 2008 ; 9: 465-471.
17. Allergan Pharmaceuticals, Inc. Data on file.
18. Schröder S., Jetter A., Zaigler M., et al. Absorption pattern of trospium chloride along the human gastrointestinal tract assessed using local enteral administration. Int J Clin Pharmacol Ther. 2004 ; 42: 543-549.